← Back to Search

Advanced Imaging for Brain Cancer

Phase 1

Recruiting

Led By Dawid Schellingerhout, MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants is >18 years old. The pediatric population has a different disease profile from adult glioma participants. To reduce heterogeneity in the patient population we will not consider participants younger than 18 for this study.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion; an average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to determine if advanced imaging techniques can distinguish between true progression of a disease (where the disease has actually worsened) and pseudoprogression (where the disease only appears to have worsened

Who is the study for?

This trial is for individuals with brain tumors who may be experiencing either true progression or pseudoprogression. Specific eligibility criteria are not provided, but typically participants would need to meet certain health standards and have a diagnosis relevant to the study.

What is being tested?

The trial is testing whether advanced MRI and CT scans, along with biopsies when necessary, can accurately differentiate between actual tumor growth (true progression) and false signs of tumor growth (pseudoprogression).

What are the potential side effects?

Potential side effects from participating in this trial mainly involve risks associated with MRI and CT scans such as discomfort from lying still, loud noises during the scan, and exposure to radiation in the case of CT. Biopsy procedures carry risks like bleeding or infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion; an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion; an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Safety and adverse events (AEs)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Arm 1Experimental Treatment3 Interventions

The tests and procedures done as part of your standard-of-care biopsy preparation, participants will also have advanced MRI and CT scans performed no later than 2 weeks before the biopsy. Typically, these scans are done within 1 or 2 days before surgery to provide the most accurate images to the surgeon.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Biopsy

2014

Completed Phase 4

~1150

CT Scan

2016

Completed Phase 2

~570